Correlation of the clinical progression with the degree and pattern of atrophy in patients with multiple sclerosis treated cladribine tablets

被引：0
|
作者：
Pogoda-Wesolowska, Aleksandra [1 ]
Aftyka, Joanna [2 ]
Zegadlo, Arkadiusz [3 ]
Staszewski, Jacek [1 ]
Stepien, Adam [1 ]
机构：
[1] Mil Inst Med, Natl Res Inst, Neurol Clin, Warsaw, Poland
[2] Warsaw Univ Technol, Fac Phys, Warsaw, Poland
[3] Mil Inst Med, Natl Res Inst, Dept Med Radiol, Warsaw, Poland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1871/4301
引用
收藏
页码：1252 / 1253
页数：2
相关论文
共 50 条
  • [21] Cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis of safety from the multiple sclerosis clinical development program
    Cook, S.
    Leist, T.
    Comi, G.
    Montalban, X.
    Sylvester, E.
    Hicking, C.
    Dangond, F.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 305 - 306
  • [22] Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets
    Gasperini, Claudio
    Ruggieri, Serena
    Pozzilli, Carlo
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2010, 6 : 391 - 399
  • [23] An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis
    Galazka, A.
    Nolting, A.
    Cook, S.
    Leist, T.
    Comi, G.
    Montalban, X.
    Hicking, C.
    Dangond, F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 133 - 133
  • [24] AN ANALYSIS OF MALIGNANCY RISK IN THE CLINICAL DEVELOPMENT PROGRAMME OF CLADRIBINE TABLETS IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
    Galazka, Andrew
    Nolting, Axel
    Cook, Stuart
    Leist, Thomas
    Comi, Giancarlo
    Montalban, Xavier
    Hicking, Christine
    King, John
    Dangond, Fernando
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (06): : E17 - E17
  • [25] Cladribine Tablets' Potential in Multiple Sclerosis Treatment
    Costello, Kathleen
    Sipe, Jack C.
    JOURNAL OF NEUROSCIENCE NURSING, 2008, 40 (05) : 275 - 280
  • [26] Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets
    Jack, Dominic
    Nolting, Axel
    Galazka, Andrew
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
  • [27] 2-year follow-up of Finnish multiple sclerosis patients treated with cladribine tablets
    Rauma, I.
    Viitala, M.
    Atula, S.
    Kuusisto, H.
    Sipila, J.
    Ryytty, M.
    Soilu-Hanninen, M.
    Jarvinen, E.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 586 - 587
  • [28] Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4
    Centonze, Diego
    Amato, Maria Pia
    Brescia Morra, Vincenzo
    Cocco, Eleonora
    De Stefano, Nicola
    Gasperini, Claudio
    Gallo, Paolo
    Pozzilli, Carlo
    Trojano, Maria
    Filippi, Massimo
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2023, 16
  • [29] Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4
    Centonze, Diego
    Amato, Maria Pia
    Morra, Vincenzo Brescia
    Cocco, Eleonora
    De Stefano, Nicola
    Gasperini, Claudio
    Gallo, Paolo
    Pozzilli, Carlo
    Trojano, Maria
    Filippi, Massimo
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2023, 16
  • [30] Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4
    Meuth, Sven G.
    Bayas, Antonios
    Kallmann, Boris
    Linker, Ralf
    Rieckmann, Peter
    Wattjes, Mike P.
    Maeurer, Mathias
    Kleinschnitz, Christoph
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (13) : 1503 - 1510
12345